Podcasts about Precision medicine

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Does personalized precision medicine have the potential to treat chronic and life-threatening diseases like cancer and enhance longevity? In this episode, we connect with Dr. John Oertle, the Chief Medical Director at Envita Medical Centers, to dive into the innovative field of personalized precision medicine – something that has played a critical role in helping many late-stage cancer patients recover holistically… Dr. Oertle specializes in chronic infectious disease, immunotherapy, and precision oncology. He leads the molecular tumor board for Envita Medical Centers and does research and development in the fields of oncology and infectious disease. Dr. Oertle and his team treat diseases by identifying and addressing the root causative factors, considering the detailed genetics, epigenetics, pharmacogenomics, environmental, and other factors that contribute to patient recovery.  Want to learn how this level of in-depth analysis can help build a customized treatment protocol for each individual patient? What does it mean to go beyond the standard one-size-fits-all protocols? Join the conversation now to find out!  Hit play to discover: ●      Why focusing on outcomes is so critical to effectively treating chronic diseases. ●      The benefits of providing individualized cancer therapy.  ●      How to teach the immune system to attack harmful tumors.  ●      The role that biological age plays in disease prevention and recovery. Click here to follow along with Dr. Oertle and his important work at Envita Medical Centers!

Kurt Lunkwitz, Chief Operating Officer at ProRx Pharma, describes the role compound pharmacies play in filling gaps when certain drugs are in short supply and providing personalized medications for patients. Compound pharmacies offer a wide range of customized formulations and delivery methods to meet the specific needs of patients, particularly in the areas of functional and preventative medicines. These pharmacies are enabling a shift towards precision medicine and individualized care, responding to the market demand for alternative and preferred formulations of medications.  Kurt explains, "There's primary clientele and then there's secondary clientele. Our primary clientele includes a host of prescribers, medical clinics, and could be telemedicine-type companies, and med spas. There are tens of thousands of these types of practitioner offices across the country, and it's a wide and booming industry as it relates to functional medicine, alternative medicine, or as we like to refer to it, preventative care. And the secondary customer would be the patient themselves. So the medications that ProRx is compounding would be ordered through these physicians' offices, these practices, and for their particular patient and customer base." "One of the primary functions in the role of a 503 B outsourcing facility, or a number of them across the country, is to step in and fill this gap. If the primary manufacturer, the pharmaceutical manufacturer, has a disruption in the supply chain, or simply just can't keep up with the demand." "If we want to take a look at one of the largest supply chain gaps that has existed, and it's been a very popular topic of conversation here more recently, this would relate a lot to some of the GLP-1 medications, both semaglutide and tirzepatide. So these were two medications that ProRx participated in and helped to fill the shortage gap. There were a handful of months where ProRx went into production, and we helped to fill tens of thousands of prescriptions for patients of medical necessity who badly needed these medications."  #ProRxPharma #CompoundPharmacy #DrugShortageList  prorxpharma.com Download the transcript here

Kurt Lunkwitz, Chief Operating Officer at ProRx Pharma, describes the role compound pharmacies play in filling gaps when certain drugs are in short supply and providing personalized medications for patients. Compound pharmacies offer a wide range of customized formulations and delivery methods to meet the specific needs of patients, particularly in the areas of functional and preventative medicines. These pharmacies are enabling a shift towards precision medicine and individualized care, responding to the market demand for alternative and preferred formulations of medications.  Kurt explains, "There's primary clientele and then there's secondary clientele. Our primary clientele includes a host of prescribers, medical clinics, and could be telemedicine-type companies, and med spas. There are tens of thousands of these types of practitioner offices across the country, and it's a wide and booming industry as it relates to functional medicine, alternative medicine, or as we like to refer to it, preventative care. And the secondary customer would be the patient themselves. So the medications that ProRx is compounding would be ordered through these physicians' offices, these practices, and for their particular patient and customer base." "One of the primary functions in the role of a 503 B outsourcing facility, or a number of them across the country, is to step in and fill this gap. If the primary manufacturer, the pharmaceutical manufacturer, has a disruption in the supply chain, or simply just can't keep up with the demand." "If we want to take a look at one of the largest supply chain gaps that has existed, and it's been a very popular topic of conversation here more recently, this would relate a lot to some of the GLP-1 medications, both semaglutide and tirzepatide. So these were two medications that ProRx participated in and helped to fill the shortage gap. There were a handful of months where ProRx went into production, and we helped to fill tens of thousands of prescriptions for patients of medical necessity who badly needed these medications."  #ProRxPharma #CompoundPharmacy #DrugShortageList  prorxpharma.com Listen to the podcast here

What does it really mean to bring precision medicine to every patient, in every community?In this inspiring, one-hour episode of the Precision Medicine Podcast, host Karan Cushman sits down with Dr. Arif Kamal, Chief Patient Officer at the American Cancer Society (ACS), for a wide-ranging conversation that reframes how we think about progress in cancer care. With a background in oncology, palliative care and health system innovation—and a personal story shaped by his mother's metastatic breast cancer diagnosis—Dr. Kamal offers a deeply human perspective on what it means to deliver not just the right treatment, but the right experience for every patient.Dr. Kamal shares how the ACS is working to make precision medicine more equitable by addressing barriers like geography, affordability, clinician burnout, and fragmented care. He explains the importance of “precision compassion”—the idea that personalized care must also include empathy, listening, and action tailored to the needs of each individual. “We can't talk about innovation,” he says, “without talking about accessibility.”From the importance of whole-person care and mobile health units in rural communities, to expanding insurance coverage for biomarker testing and building trust with patients and caregivers, this conversation is full of insight into what it will truly take to change the odds for people facing cancer.You'll also hear about the ACS's bold initiatives:The Change the Odds campaign, tackling ZIP code-driven disparities in careACS CAN's legislative efforts to expand access to biomarker testingHow the ACS's roundtables and grassroots partnerships support health systems, clinicians, and researchers nationwideDr. Kamal challenges us to think beyond science alone and focus on what really matters to patients—whether that's more time, better quality of life or simply the ability to hold a grandchild on the beach.Don't miss this conversation about how we turn precision medicine from a possibility into a promise—one rooted in empathy, equity and action.Subscribe here to catch every episode in the series "Bringing Precision Medicine to Everyone." Next, we explore the evolving world of liquid biopsy and its role in expanding access to early cancer detection and precision treatment.

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode features Dr. James Lu, CEO and Co-founder of Helix, discussing how precision medicine is evolving from specialty use to becoming a foundational element of mainstream healthcare. He explores the infrastructure, partnerships, and mindset shifts needed for health systems to scale genomic data and realize its full value.This episode is sponsored by Helix.

In this insightful interview with Blue Box Asset Mangement's Porfolio Manager Mark Dainty we talk about precision medicine and life sciences, his investment strategy, and how he constructs a portfolio of "developers" vs "enablers". We also talk about 3 stocks in the fund. We hope you enjoy listening!  *~*~*~*~*  Get access to all of Speedwell Research's in-depth Research Reports here. If you need help getting Speedwell added as an approved research vendor for your investment firm, please reach out to info@speedwellresearch.com  -*-*-*-*-*-*-*-*-*-*- Show Notes (0:00) — What is Precision Medicine and Life Sciences (11:15) — Small Markets, but Higher Prices (22:24) — Why Precision Medicine is like Dating Apps (27:56) — Investment Strategy and Portfolio Construction (47:20) — Two Stocks: Natera ($NTRA) and Guardant Health ($GH) (54:24) — Risk of the Unknown? (1:02:55) — Revolutions Medicines ($RVMD) (1:11:10) — Financial Modeling -*-*-*-*-*-*-*-*-*-*- Become a Speedwell Member here to gain access to *all* of our in-depth research reports and more!   Sign up for Speedwell's free newsletter and weekly memos here *~*~*~*~*  Follow Us: Twitter: @Speedwell_LLC Threads: @speedwell_research Email us at info@speedwellresearch.com for any questions, comments, or feedback. -*-*-*-*-*-*-*-*-*-*- Disclaimer Nothing in this podcast is investment advice nor should be construed as such. Contributors to the podcast may own securities discussed. Furthermore, accounts contributors advise on may also have positions in companies discussed. Please see our full disclaimers here:  https://speedwellresearch.com/disclaimer/

I'm beyond excited to share our latest podcast episode with you. This time, I had the pleasure of chatting with the incredible Maddi Holman, the general partner of Daring Ventures and the host of her own podcast, "Let's Be Heard." Maddi's journey from aspiring doctor to venture capitalist is nothing short of inspiring, and I can't wait for you to hear her story.Here are some of the key takeaways and intriguing insights from our conversation:

In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company's cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen's unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen's broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland's BioHealth Capital Region has supported the company's innovation and growth.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Iris Wang of the Mayo Clinic shares cutting-edge insights on gut health across the lifespan, including advancements in pharmacogenomics for personalized medication selection and innovative breathing techniques to relieve abdominal distension. She busts common myths about bloating, revealing how diaphragmatic dysfunction rather than excess gas may be the culprit. Dr. Wang also emphasizes the importance of starting gut health education early, helping kids and parents alike understand that pooping shouldn't be painful or forced. • How pharmacogenomics helps identify why some patients metabolize medications differently, leading to better medication choices with exploration on the hope and/or hype of precision medicine in the GI world (Wang et al 2019)• Explanation of abdomino-phrenic dyssynergia (APD) – when the diaphragm moves downward instead of upward, causing visible abdominal distention• Specialized breathing technique developed in Barcelona that retrain the diaphragm for bloating relief (Barba E et al 2024) - see video link below• The importance of normalizing healthy pooping habits from childhood through education & tools like toileting stools (e.g. Squatty Potty)• Warning signs for parents about childhood constipation – including stool leakage, straining, & urinary problems (Tran DL et al 2023)• How yoga can support gut health through mindful movement, core engagement, & stress reductionYoga videos:Yoga For Digestion Flow| Yoga With Adriene (26 mins)Yoga for Bloating, Digestion, Ulcerative Colitis, IBD & IBS (12 mins)Check out Dr. Wang's children's book Boo Can't Poo, which helps normalize healthy pooping habits for kids while educating parents too.References:Wang XJ, Camilleri M. Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. World J Gastroenterol. 2019 Mar 14;25(10):1185-1196.Barba E, Livovsky DM, Accarino A, Azpiroz F. Thoracoabdominal Wall Motion-Guided Biofeedback Treatment of Abdominal Distention: A Randomized Placebo-Controlled Trial. Gastroenterology. 2024;167(3):538-546.e1.Specialized breathing technique for abdominal distention: Video DemonstrationTran DL, Sintusek P. Functional constipation in children: What physicians should know. World J Gastroenterol. 2023 Feb 28;29(8):1261-1288.Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

This is not your average health conversation. Dr. Anil Bajnath joins me to decode the exposome—the totality of your lifelong exposures—and how it's quietly shaping your energy, mood, resilience, and even your future disease risk. We explore how deep data from multi‑omics testing can translate into practical steps for healing, from detox pathways and mitochondrial support to the balance between rigorous science and joy-driven living.We talk through everything from electric grounding and photobiomodulation to parenting as a longevity stressor, and how the body's “biological 401(k)” can be optimized with personalized strategies. This episode bridges ancient wisdom, futuristic science, and the very human art of transformation. Tune in for a mind-expanding look at what it means to truly know your body—and how to honor it in the most intelligent way possible.HIGHLIGHTS[00:00] - Why understanding the exposome is essential to personalized medicine[02:13] - From microbiology to multi-omics: Dr. Bajnath's origin story[06:52] - What is multi-omics? A breakdown of genomics, proteomics, microbiomics, and more[09:16] - How your environment and genetics interact to create disease—or resilience[15:53] - Why detox pathways matter more than you think[18:32] - The paradox of biohacking: when “clean living” isn't enough[24:33] - The power of grounding, electric charge, and frequency on cellular health[30:53] - A real-world case study: glyphosate exposure and recovery[35:59] - Integrating science, intuition, and technology in modern medicine[41:41] - Red blood cells, zeta potential, and PEMF therapy—explained[46:12] - The top 5 omics tests to build your personal health roadmap[52:08] - How parenting impacts longevity and what to do about it[57:44] - Big visions: democratizing access to precision health worldwideLINKS & RESOURCESDr. Anil Bajnath https://anilbajnath.comThe Institute for Human Optimizationhttps://ifho.orgUpgrade Your WellnessBEAM Minerals: http://beamminerals.com/beautifullybrokenUse code beautifullybroken for 20% offFlowpresso: https://calendly.com/freddiekimmel/flowpresso-one-on-one-discoverySilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD30% off Use Code: BEAUTIFULLYBROKEN for DiscountStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED: https://lightpathled.pxf.io/c/3438432/2059835/25794code: beautifullybroken CONNECT WITH FREDDIECheck out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Still trying to optimize your health with guesswork and generic advice?Most people settle for “one-size-fits-all” supplements and hope for the best-missing out on the breakthroughs that only real data and personalization can offer.In a world flooded with empty promises, few realize how quickly tailored, science-backed solutions can transform energy, focus, and longevity.Enter Vadim Fedotov—ex-pro athlete, CEO, and co-founder of Bioniq, the health tech company bringing truly personalized care to the world's top leaders, innovators, and athletes.In this eye-opening conversation, Vadim reveals why your biology is as unique as your fingerprint—and why the future belongs to those who personalize, measure, and adapt.Discover the systems, mindsets, and science behind optimizing human potential—without wasting time, money, or hope on outdated approaches.

In the third episode of our lung cancer miniseries, Jonathan Sackier is joined by Douglas E. Wood, Henry N. Harkins Professor and Chair of Surgery at the University of Washington. A global leader in thoracic oncology, Wood explores the critical role of lung cancer staging, the evolution of screening guidelines, and how surgical innovation is shaping the future of lung cancer treatment. Timestamps: 00:00 – Introduction 02:37 – Career beginnings 07:37 – Career highlights 11:38 – Thoracic oncology guidelines 15:26 – AI and big data 17:17 – Expanding lung cancer screening 19:29 – Robotic surgery 23:38 – Targeted therapies 27:23 – Cancer staging 30:44 – Lung volume reduction surgery 35:10 – Current trials 40:50 – Three wishes for healthcare

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breast cancer is one of the most talked-about health issues in the world, but there's still so much we don't discuss. While mammograms and early detection campaigns have saved countless lives, the conversation often stops there.  What's missing is a deeper look at the lifestyle, genetic, and environmental factors that play a pivotal role in prevention, and the small, daily changes that can make a massive impact. Because here's the truth: 80% of breast cancer cases are not inherited. They're environmental. That means we have far more power than we think. But to tap into it, we need better guidance, smarter screening strategies, and a stronger understanding of how our bodies work. What kind of screenings should women get? How do factors like breast tissue increase the risk of breast cancer? In this episode, I'm joined by Dr. Pamela Smith, an internationally recognized functional medicine physician, author of 14 bestselling books, and co-director of the Personalized Medicine Certification at the University of South Florida.  She shares science-backed strategies to reduce your risk, strengthen your immune system, and support your body before and after a diagnosis. Things You'll Learn In This Episode  The 3 things that feed cancer Sugar, stress, and toxins are the trifecta that fuel cancer cell growth. But how do you realistically cut them out and what's secretly making them worse? Why 80% of breast cancer isn't genetic Family history matters but not as much as your environment. Which everyday exposures and habits have the biggest impact on your risk? The truth about hormones and alcohol Is hormone therapy safe? And what happens when you mix it with alcohol?  What most women don't know about screening Dense breast tissue, faulty methylation, even your gut health can affect your screening results. How do you make sure you're getting the full picture of your health?   Guest Bio Pamela Wartian Smith, M.D., MPH, MS is an internationally known speaker and author on the subject of Anti-Aging and Precision Medicine. She spent her first twenty years of practice as an emergency room physician with the Detroit Medical Center in a level 1 trauma center and then 28 years as an Anti-Aging/Functional Medicine specialist. She is a diplomat of the Board of the American Academy of Anti-Aging Physicians and is. Dr. Smith also holds a master's degree in public health and a master's degree in metabolic and nutritional medicine. She is in private practice and is the senior partner for The Center for Precision Medicine, with offices in Michigan and Florida. She has been featured on CNN, PBS, and many other television networks, has been interviewed in numerous consumer magazines, and has hosted two of her own radio shows. Dr. Smith was one of the featured physicians on the PBS series “The Embrace of Aging” as well as the online medical series “Awakening from Alzheimer's” and “Regain Your Brain”. She is the author of fourteen best-selling books, including How to Prevent Breast Cancer- Before & After: A Guide to Taking Back Control of Your Life. To learn more about Dr. Smith and to get her books, visit https://mdpamelasmith.com/.    About Your Host Hosted by Dr. Deepa Grandon, MD MBA, triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidenced-based lifestyle medicine.     ​​ Resources Feeling stuck and want guidance on how to transform your spiritual, mental and physical well being? Get access to Dr Deepa's 6 Pillars of Health video! Visit drdeepa-tlc.org to subscribe and watch the video for free. ‌ Work with Me Ready to explore a personalized wellness journey with Dr. Deepa? Visit drdeepa-tlc.org and click on “Work with Me” to schedule a free intake call. Together, we'll see if this exclusive program aligns with your needs!  Want to receive a devotional every week From Dr. Deepa? Devotionals are dedicated to providing you with a moment of reflection, inspiration, and spiritual growth each week, delivered right to your inbox. Visit https://www.drdeepa-tlc.org/devotional-opt-in to subscribe for free. Ready to deepen your understanding of trauma and kick start your healing journey? Explore a range of online and onsite courses designed to equip you with practical and affordable tools. From counselors, ministry leaders, and educators to couples, parents and individuals seeking help for themselves, there's a powerful course for everyone. Browse all the courses now to start your journey.   ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced. Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm so our show reaches more people. Thank you!

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textWhat if healthcare wasn't about fixing what's broken—but unlocking what's possible?

If you've been feeling off in your 30s, 40s, or 50s—tired, bloated, gaining weight despite healthy habits—you're not imagining it. These are common signs that your metabolism, hormones, and overall biochemistry are shifting. But here's the problem: most advice still treats women like we're all the same.In this episode of Sofia Unfiltered, we talk with Dr. Onikepe “Onyx” Adegbola, a physician-scientist and expert in lifestyle, menopause, and obesity medicine. She's also the founder of Casa de Sante, a health tech company using AI and personalized diagnostics to transform how adults approach their health.Together, we explore:What's actually changing in your body during midlifeWhy generic weight loss or “just eat less” advice failsHow AI and advanced testing are reshaping personalized careSimple, science-backed changes you can start todayIf you're ready to stop guessing and start getting real answers about your health, hormones, and energy, this is your starting point.

How do you lead at the cutting edge of health, data, and AI—while staying deeply human?Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe's most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn't just her technical fluency—it's her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation.In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you're an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare.Here's what you'll take away:Why most AI projects fail—and how to spot the ones that won't.How to lead technical teams with vision, warmth, and accountability.Why proprietary data matters more than fancy algorithms.What real innovation feels like—and how to know when you're missing it.At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters.As she says: “Start with the real problem. If you don't understand the problem, AI won't help you.”Timestamps & Topics

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

Send us a textWhat if your medications are working against you?Jim Wallace, former CEO of DecisionRx and Author of "Precision Medicine: AI and the Science of Personalized Healthcare," joins CareTalk to expose the massive issue of medication misfires and how pharmacogenomics can help fix it.From his time at SpaceX to leading innovation in personalized medicine, Jim explains why your DNA holds the key to safer, more effective care—and why you might not want to wait for your doctor or insurer to catch up.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today we have Dr. Michael A. Schmidt, the founder, CEO, and Chief Scientific Officer of Sovaris Aerospace, a company focused on assessments and solutions applied to humans in space and extreme environments on Earth.  Michael is also a professor of aerospace medicine at the University of Central Florida College of Medicine, one of the few programs in the U.S. that offers a medical residency in aerospace medicine. Michael is known for his work pioneering the field of precision medicine. He uses molecular analytics, coupled with physiologic and behavioral assessments, to facilitate human performance and resilience on Earth as well as in the extreme environment of space. His work covers a spectrum from NASA, the NFL, the NBA, U.S. Olympic teams, Nike, SpaceX, Axiom Space, NASCAR, Special Operations, the Naval Submarine Medical Research Lab, the Mayo Clinic, and others. We had a long and fascinating conversation with Michael and decided to break the interview into two parts. This episode focuses on Michael's background and the cognitive and physical challenges astronauts experience in spaceflight. We also dive into the many ways that precision medicine is facilitating human performance and resilience here on Earth. In part two of our conversation, Michael talks about his work with NASA and SpaceX on the challenges of civilian spaceflight and the future of Mars exploration, including the construction of permanent colonies on the Moon and Mars. You won't want to miss that conversation. Show notes: [00:03:59] Dawn opens our interview mentioning that Michael grew up in Minnesota in a small farming community, asking if it's true that he sometimes had to do chores in 20- to 30-degree weather. [00:06:50] Dawn asks if it is true that Michael fell in love with science at a young age, even building telescopes at the age of 11. [00:08:00] Dawn asks Michael what it was that led him to become so fascinated with space specifically. [00:08:58] Dawn asks if Michael ever thought about becoming an astronaut. [00:10:09] Ken asks if it is true that Michael was a big reader as a child. [00:11:21] Dawn asks Michael to talk about his childhood athletic interests. [00:11:55] Dawn asks how it was that a high school quarterback from a small town in Minnesota ended up at university in the United Kingdom. [00:13:38] Ken asks Michael what years he worked at NASA Ames Research Center. [00:14:51] Ken mentions that when Michael was at NASA Ames, he did work collecting molecular and physiologic assessments of humans using NASA's 20-G centrifuge. Ken asks Michael to talk about the centrifuge and how he used it in his studies of hypergravity. [00:17:49] Ken comments on the fact that pieces of equipment like NASA's 20-G centrifuge are a precious scientific resource, and when they cease functioning, unfortunately, they are unlikely to be replaced. [00:19:40] Ken and Michael discuss the fact that microgravity, despite being one of the most pressing effects on astronaut health, is the one of the least addressed problems in human spaceflight. [00:21:48] Ken explains that Michael is the founder, CEO and Chief Scientific Officer of a company called Sovaris Aerospace, which is focused on assessments and solutions applied to humans in space and extreme environments on Earth. Ken asks Michael where the idea came from to found this company. [00:24:35] Dawn explains that since the human genome was first sequenced, there has been an acceleration of genome-based technologies that have made it possible to consider a person's genetic makeup, both in healthcare and optimizing performance. Dawn asks Michael to talk about the work he does applying genomics to human spaceflight. [00:28:52] Dawn asks about Michael's direction of the molecular profiling and precision medicine efforts for the Golden State Warriors during their record-breaking 73-9 season [00:32:57] Dawn mentions that Michael published a review in the journal Meta...

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kara Werner, VP & GM at Tempus AI, joins Kellogg MBA student Ashley Lemon to discuss how Tempus makes patient data meaningful - enabling earlier cancer diagnoses and accessible precision medicine. They also discuss Kara's career journey at the healthtech startup and advice for MBAs looking to break into the space.LinkedInTimestamps:(1:47) Kara's why: from Kellogg to Tempus AI(4:17) Fixing what's broken: structuring and operationalizing multimodal patient data(10:08) Tempus's edge: RNA & DNA, AI-enabled diagnostics platform & strategic partnerships (14:58) AI in action: how Tempus One, Lens & Next connect patients to trials and testing to close care gaps(18:27) Standing up pharma biz: building and adapting for a new client(26:02) What Kara's excited about: tissue-sparing RNA for identifying ADC candidates(28:55) MBA advice: taking Medvec's Negotiations, welcoming challenge, pivoting with purpose(36:24) Wildest & craziest dream: travel experience curator!Visit our podcast page for more episodes on trends and innovation in healthcare and follow our socials so you never miss an update.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Tracy Gapin, MD, FACS, is a renowned expert in men's health optimization and longevity, with over 25 years of experience as a board-certified urologist. He founded the Gapin Institute to help high-performing individuals, including entrepreneurs, executives, and athletes, achieve peak performance through personalized health programs. Dr. Gapin integrates advanced diagnostics, epigenetics, hormone therapy, and wearable technology to monitor and transform his clients' health, focusing on sustainable, measurable outcomes. A thought leader and author of bestsellers Male 2.0 and Codes of Longevity, Dr. Gapin has been featured on NBC, Entrepreneur Magazine, and at Dave Asprey's Biohacking Conference. He is a member of the American Academy of Anti-Aging, the Age Management Medical Group, and the International Peptide Society. In this episode Dr. Tracy dives in to talk about what re-shaped his thinking on the traditional reactive medical system, and the path he was inspired to take to become a proactive solution for high-performing entrepreneurs and leaders. Dr. Tracy walks us through how we may overestimate what we think we know about our health which are our health blind spots. These can show up when we dive deeper beyond the surface to explore things such as hormones, inflammation, and our gut health. Dr. Tracy shares his personal story of dis-ease and what it finally took for him not only to face his health head-on but also the medical system he operated within. Patrick and Dr. Tracy explore his paradigm shift around men's and women's health, endocrine disruptors, peptides, protein and carbs, aging and regenerative medicine. They round out their conversation with mindset – habits, choice, discipline and transformation. You don't want to miss it!

I interviewed James Lu, CEO of Helix, about precision medicine and whether it has been successful in terms of practical applications that improve patients' lives.   Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com  https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Connect with James Lu https://www.linkedin.com/in/james-lu-m-d-ph-d-8450334/    Review, Subscribe and Share If you like what you hear please leave a review by clicking here   Make sure you're subscribed to the podcast so you get the latest episodes. Click here to subscribe with Apple Podcasts  Click here to subscribe with Spotify Click here to subscribe with Podbean Click here to subscribe with RSS  

In this forward-looking episode of the SCCM Podcast, Daniel F. McAuley, MD, explores how the clinical and research communities are rethinking acute respiratory distress syndrome (ARDS), shifting from a one-size-fits-all model to a focus on identifying and targeting modifiable traits. Building on his Thought Leader Session at the 2024 Critical Care Congress, Dr. McAuley unpacks the major thematic shift toward precision medicine in critical care. Instead of treating ARDS as a single, homogenous condition, researchers are increasingly identifying biologically distinct subgroups—especially hyper- and hypoinflammatory phenotypes—that may respond differently to therapies. These insights are fueling a new generation of trials that aim to prospectively apply this knowledge to treatment strategies. Central to this evolution is the Precision medicine Adaptive platform Network Trial in Hypoaemic acutE respiratory failure (PANTHER), of which Dr. McAuley is a team member. PANTHER is a Bayesian adaptive platform randomized clinical trial studying novel interventions to improve outcomes for patients with acute hypoxemic respiratory failure. Designed to be adaptive and biomarker informed, PANTHER will test therapies such as simvastatin and baricitinib, based on real-time phenotyping of patients with ARDS. Throughout the episode, Dr. McAuley reflects on how advances in machine learning and biomarker identification are making precision treatment more feasible. He discusses the importance of maintaining evidence-based supportive care, such as lung-protective ventilation and prone positioning, while integrating new targeted therapies. Discover the latest investigations into potential therapeutic agents—including mesenchymal stromal cells, statins, and extracorporeal carbon dioxide removal—as Dr. McAuley aims to translate early findings into tangible improvements in patient outcomes. This episode offers critical insights into the changing landscape of ARDS research and patient care, as Dr. McAuley articulates a hopeful vision for the future—one in which targeted, individualized treatments can improve outcomes for patients with one of critical care's most challenging conditions. Dr. McAuley is a consultant and professor in intensive care medicine in the regional intensive care unit at the Royal Victoria Hospital and Queen's University of Belfast. He is program director for the  Medical Research Council/National Institute for Health and Care Research (MRC/NIHR) Efficacy and Mechanism Evaluation Program and scientific director for programs in NIHR.   Access Dr. McAuley's Congress Thought Leader Session, ARDS: From Treating a Syndrome to Identifying Modifiable Traits here.

Ever thought about why medications work differently for different people? In this episode of Absolute Gene-ius, we explore the exciting field of pharmacogenomics with Wendy Wang, pharmacogenetic laboratory supervisor at Children's Mercy Hospital in Kansas City. Wendy shares how genetics can influence drug metabolism, offering a glimpse into how precision medicine can revolutionize healthcare by tailoring treatments based on an individual's unique genetic makeup.At the heart of Wendy's research is CYP2D6, a cytochrome P450 enzyme responsible for metabolizing around 20% of all prescribed medications. She explains how her lab uses digital PCR to analyze copy number variations (CNV), offering a reliable and precise method to predict drug metabolism. Wendy dives into the complexities of structural variants, the role of digital PCR in enhancing assay efficiency, and why pharmacogenomics is a critical piece of the precision medicine puzzle. Her use of delightful metaphors—like comparing genetic testing to ladling soup—makes complex science both relatable and engaging.In the Career Corner, Wendy opens up about her winding path to molecular biology, which included studying classical antiquity and nearly pursuing a career in history. She emphasizes the importance of resilience in research, embracing failure as a learning opportunity, and encourages budding scientists to reach out to mentors and explore diverse interests. Plus, hear about her most embarrassing lab mishap (hint: it involves a fire alarm) and the proud moment of publishing her first, first-author paper.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This lecture is entitled Populations, Persons, and Precision Medicine: The Ethics of Emerging Information Technologies. It was presented by Paul Scherz of (then) the University of Virginia on March 22, 2024, at the University of Chicago.

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support.   What if AI could predict exactly when you'd get sick—and help you prevent it?   In this episode of Eye on AI, Dr. Eric Topol, world-renowned cardiologist, author, and AI health pioneer, joins us to unveil the future of preventive medicine. We dive deep into the themes of his new book Super Agers, which lays out a groundbreaking blueprint for extending healthspan—not just lifespan—through the power of multimodal AI and deep biological data.   Dr. Topol explains how AI models can now analyze a full-stack of human data—genomics, proteomics, metabolomics, microbiome, and more—to forecast age-related diseases like cancer, Alzheimer's, and heart disease decades before symptoms appear. This isn't science fiction. It's here now.   If you're interested in the intersection of AI, longevity, and the future of medicine, this is a must-listen.   Where AI Works tackles the big questions shaping AI's role in business today, cutting through the hype to deliver actionable insights for leaders. Brought to you by the Wharton School, in collaboration with Accenture, this podcast combines cutting-edge research with real-world case studies to uncover how top companies are using AI to upskill workforces, enhance customer experiences, boost productivity, and streamline operations.  Check it out:  https://link.cohostpodcasting.com/f5e223b4-da0c-4fc8-bbf3-5f24c15f8fd2?d=sxo9xhJN2    Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) The Power of Precision Medical Forecasting (01:53) Eric Topol's Journey into Digital & AI Medicine (03:27) Using AI to Prevent Aging-Related Diseases (05:25) The Challenge of Health Data Privacy & Ownership (09:05) Genetic Risk to Deep Data Insights (11:20) Personalized Prevention Through Lifestyle & Biomarkers (13:59) Why Anti-Aging Drugs Are Still Years Away (16:18) What are Organ Clocks (19:34) The Longevity Industry's Flawed Use of AI (21:59) Top AI Pioneers Endorse “Super Agers” (24:21) Which Longevity Startups Are Getting It Right? (26:27) Why Topol Refuses to Join Longevity Startups (28:57) Topol's Own Health Data & Lessons Learned (30:25) How Accurate Is AI at Predicting Disease Timing? (31:47) The Truth About Genetic Risk and Cancer Detection (33:33) AI-Driven Cancer Detection: A Smarter Approach (38:51) How Precision Medicine Has Evolved (41:02) The Risky Reality of Anti-Aging Interventions (44:39) Why Healthspan Matters More Than Lifespan

Susan Athey, PhD, of Standford University joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss her research on machine learning to target behavioral nudges for college students and their potential implications for health care. Related Content: How an Economist's Application of Machine Learning to Target Nudges Applies to Precision Medicine

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

View the Show Notes For This Episode Dr. Kristine Burke discusses the Prevention and Reversal of Neurological Conditions with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights       ________________________________________________________________________________________________________ Dr. Kristine Burke is a triple board-certified Precision Medicine Physician, Author, Educator, and Researcher.  She is an expert on the prevention and reversal of chronic diseases such as dementia, diabetes, and heart disease. She is the Chief Medical Director and the CEO of Precision Medicine in Northern California. Her website is Truehealthcpm.com. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

There's a care model for schizophrenia that actually works—why isn't it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.Also discussed:The first novel schizophrenia drug in over 50 years (Cobenfy)Why clozapine is underused—and how that may finally changeThe potential of brain imaging and biomarkers in psychiatric treatmentWhat a real community mental health system looks likeWhy trust, not just treatment, is essential for recovery

In this episode, we delve into our latest biohacking experiments and share insights from recent interviews with leading experts in the health and wellness space. We discuss the concept of "bioharmonizing" with Dr. Melissa Sonners, a functional medicine approach to thyroid conditions like Hashimoto's with Dr. Heather Stone, PEMF technology with Mike & Alyssa from Align Mat, the role of genomics in precision medicine with Dr. Matt Dawson from Wild Health, and the emotional aspects of fertility with Beth Gulotta from Quiet the Clock. Join us for this fun and inspiring conversation!SHOW NOTES:0:39 Welcome to the show!2:57 Renee's current sleep experiment8:59 Cell detox & parasite cleansing12:02 Most recent podcast recap12:57 Ep 289: Dr Melissa Sonners14:21 Getting over people-pleasing16:59 Ep 290: Dr Heather Stone18:03 Gaslighting from doctors20:40 Missing nutrition link for Hashimoto's22:56 Ep 291: Mike & Alyssa of Align Mat24:25 All the PEMF mats we've tried28:10 *PIQUE TEA*30:21 *ALIGN MAT*31:58 Ep 292: Wild Health34:32 Are higher fat diets for you?37:14 Ep 293: Beth Gulotta40:31 Importance of getting into parasympathetic42:23 Noticing the ‘Red Ferrari'43:47 Upcoming EventsRESOURCES:Onera At-Home Sleep StudyALIGN MAT - Save $250 with code: BIOHACKERBABESPIQUE TEABe Inspired Mama - Dr. Melissa SonnersWild HealthQuiet the Clock - Beth GulottaUltimate Wellness in Miami - Save with code: BIOHACKERBABESHealthspan SummitHack Your Health in Tampa - Save with code: BIOHACKERBABESOur Sponsors:* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Dr. Florence Comite, MD is a clinician-scientist, endocrinologist, and the leading expert in the fields of healthy longevity and precision medicine. Her international reputation stems from her innovative approach to leveraging proprietary clinical and wearable data in her private clinical and virtual practice to detect, predict, and reverse biological aging, while optimizing health and vitality.   As a graduate of Yale School of Medicine, Dr. Comite served as a faculty member for twenty-five years with a distinguished triple appointment in Endocrinology (Internal Medicine and Pediatrics) and Reproductive Endocrinology (Gynecology and Andrology). During her career, she trained at the National Institutes of Health and founded Women's Health at Yale, establishing the nation's first women-only clinic.   In 2005, Dr. Comite founded the Comite Center for Precision Medicine & Healthy Longevity in New York City, where she developed the groundbreaking Nof1™ clinical process, treating each patient as a single subject clinical trial. The Center's success has led to expansions in Palo Alto and Miami Beach. Her innovative approach has attracted a global clientele, including forward-thinking physicians, industry leaders, and entrepreneurs, each receiving personalized healthcare interventions tailored to their individual needs. Her commitment to advancing medical science is evident through her extensive research and publications in prestigious journals such as the New England Journal of Medicine, JAMA: The Journal of the American Medical Association, and the Journal of the Endocrine Society. Dr. Comite's pioneering research spans across children, women, and men, recognizing the critical role of the entire system in aging and disease.   In 2013, she authored the bestselling book "Keep It Up: The Power of Precision Medicine to Conquer Low T and Revitalize Your Life," focusing on androgen deficiency and vitality in aging men. Her next book, "Invincible: Eliminate the Disorders of Aging for a Healthy, Long Life," will be published by Little Brown, Spark in Spring 2026. Through her startup Groq Health, Dr. Comite is scaling her precise methodology of precision medicine to a digital clinic delivered virtually.   As a sought-after keynote speaker, Dr. Comite continues to captivate audiences worldwide, sharing her expertise and vision for the future of precision medicine and healthy longevity.

This Saturday on The Heart of Innovation, Emmy Award-winning Journalist Kym McNicholas and Interventional Cardiologist Dr. John Phillips welcome James Maskell to discuss TruNeura, founded by Dr. Kristine Burke, to pioneer personalized medicine for Alzheimer's and dementia. Inspired by innovative treatments that helped his own father, Maskell will share how TruNeura's precision medicine approach is creating new possibilities for patients with cognitive decline. The conversation will explore how vascular health impacts brain function, with special attention to how arterial buildup restricts critical blood flow to the brain. Get an exclusive preview of the upcoming Alzheimer's Summit starting Tuesday, where experts will gather to discuss the latest advances in cognitive health. While challenging, these new approaches offer hope for many families. Join us for this important conversation and visit truneura.com to learn more about the company and drtalks.com/summit/alzheimers for summit information. #AlzheimersResearch #PrecisionMedicine #CognitiveHealth #peripheralarterydisease #padsupport #globalpadassociation #theheartofinnovation

In this episode, we sit down with Dr. Matthew Dawson, the founder and CEO of Wild Health, and leader in genomics-based precision medicine. Dr. Matt breaks down what precision medicine truly means--how it goes beyond traditional healthcare to create highly personalized plans based on your unique genetic blueprint and blood work. We explore some of the most important genes to assess for optimizing health, performance, and longevity, including the ApoE gene. He shares powerful insights into the future of medicine and why understanding your genetics is crucial for extending healthspan. Plus, we open up about our own personal Wild Health test results and how they've shaped our individual wellness journey. This conversation is packed with actionable insights you won't want to miss!Dr. Matthew Dawson is the founder and CEO of Wild Health, a genomics-based precision medicine company, and the CEO of TruDiagnostic, an epigenetics testing lab. He has authored two textbooks, published over two dozen studies, lectured in over 20 countries, and won national awards for education and innovation. His passion is unlocking the secrets of the genome and epigenome and using them to optimize health and maximize healthspan. He lives in the woods with his wife, four children, and two dogs.SHOW NOTES: 0:31 Welcome to the show!3:57 Dr. Matt Dawson's Bio4:40 Welcome Dr. Matt to the show!5:14 What is “Precision Medicine”?7:14 Your genes are not your destiny11:09 Renee's experience with Bulletproof coffee11:38 MTHFR & Homocysteine12:43 Combining lab work with genetics17:24 Alzheimer's genetics20:32 What to do for APOE-3/422:56 Biomarkers for optimal health 24:28 Can you change your sleep chronotype?28:26 Genes for telomere length31:37 *ALIGN MAT*33:16 *PIQUE TEA*35:27 Boosting BDNF37:30 Something new about HbA1C!39:47 FOXO3 Gene for Longevity43:40 Blue Zones & social connection45:12 Testing Biological Age49:08 Caloric Restriction for Longevity51:42 The perfect diet for your genes53:25 Comparing macro tolerances57:37 Wild Health reports 59:12 Coming soon for Precision Medicine!1:04:16 His final piece of advice1:04:56 Thanks for tuning in!RESOURCES:Website: wildhealth.com - discount code: BIOHACKERBABESInstagram: wildhealthmdLinkedIn: Wild HealthMy Align Mat - discount code: BIOHACKERBABES to save $250Pique Tea - Save $ with this link!Puori - Save 20% with discount code: BIOHACKERBABESEffecty - Save $50 with discount code: BIOHACKERBABESOur Sponsors:* Check out Effecty and use my code BIOHACKERBABES for a great deal: https://www.effecty.com* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands